Safety of infliximab treatment in patients with rheumatoid arthritis in a real-world clinical setting: Description and evaluation of infusion reactions

Journal of Rheumatology

Volumn 39, Issue 8, 2012, Pages 1539-1545

  Kelsall, John ^a,b,c   Rogers, Pamela ^d   Galindo, Griselda ^d   De Vera, Mary A ^d  

^a Mary Pack Arthritis Centre   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c ST PAUL S HOSPITAL   (Canada)

^d ARTHRITIS RESEARCH CENTRE OF CANADA   (Canada)

Author keywords

Infliximab; Infusion reactions; Rheumatoid arthritis

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; INFLIXIMAB;

ABDOMINAL PAIN; ACUTE INFUSION REACTION; ADULT; ANXIETY; ARTHRITIS; ARTICLE; BACKACHE; BRADYCARDIA; CHEST TIGHTNESS; CHILL; COHORT ANALYSIS; COUGHING; DELAYED INFUSION REACTION; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DRUG SAFETY; DYSPNEA; ERYTHEMA; EYE SWELLING; FATIGUE; FEMALE; FEVER; FLUSHING; HEAD; HEADACHE; HEART ATRIUM FIBRILLATION; HEART PALPITATION; HUMAN; HYPERTENSION; HYPERVENTILATION; HYPOTENSION; INFUSION RELATED REACTION; INJECTION SITE REACTION; LIBIDO DISORDER; MAJOR CLINICAL STUDY; MALAISE; MALE; NAUSEA; NECK; PALLOR; PARESTHESIA; PRIORITY JOURNAL; PRURITUS; RASH; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; RHINITIS; RIGOR; SIDE EFFECT; SWEATING; TACHYCARDIA; THORAX PAIN; THROAT IRRITATION; TREATMENT OUTCOME; TREATMENT RESPONSE; URTICARIA; VOMITING; XEROSTOMIA;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84864552433     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.110956     Document Type: Article

References (12)

1. Cheifetz A, Mayer L. Monoclonal antibodies, immunogenicity, and associated infusion reactions. Mt Sinai J Med 2005;72:250-6. (Pubitemid 41052052)
2. St. Clair EW, van der Heijde DM, Smolen JS, Maini RN, Bathon JM, Emery P, et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Phase III ASPIRE study. Arthritis Rheum 2004;50:3432-43. (Pubitemid 39488667)
3. Maini R, St. Clair ET, Breedveld F, Furst D, Kalden J, Weisman M, et al. Infliximab (chimeric anti-tumour necrosis factor a monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomized phase III trial (ATTRACT). Lancet 1999;354:1932-9.
4. Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor a monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998;41:1552-63. (Pubitemid 28459913)
5. Lipsky PE, van der Heijde DM, St. Clair EW, Furst DE, Breedveld FC, Kalden JR, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000;343:1594-602.
6. Westhovens R, Yocum D, Han J, Berman A, Strusber I, Geusens P, et al START Group. The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various co-morbidities. Phase III START Group. Arthritis Rheum 2006;54:1075-86. (Pubitemid 43672920)
7. Rahman MU, Strusberg I, Geusens P, Berman A, Yocum D, Baker D, et al. Double-blinded infliximab dose escalation in patients with rheumatoid arthritis. Ann Rheum Dis 2007;66:1233-8. (Pubitemid 47309743)
8. Ducharme J, Pelletier C, Zacharias R. The safety of infliximab infusions in the community setting. Can J Gastroenterol 2010;24:307-11.
9. Wasserman MJ, Weber DA, Guthrie JA, Bykerk VP, Lee P, Keystone EC. Infusion-related reactions to infliximab in patients with rheumatoid arthritis in a clinical practice setting: Relationship to dose, antihistamine pre-treatment, and infusion number. J Rheumatol 2004;31:1912-7. (Pubitemid 39336713)
10. Lequerré T, Vittecoq O, Klemmer N, Goëb V, Pouplin S, Menard JF, et al. Management of infusion reactions to infliximab in patients with rheumatoid arthritis or spondyloarthritis: Experience from an immunotherapy unit of rheumatology. J Rheumatol 2006;33:1307-14.
11. Cheifetz A, Smedley M, Martin S, Reiter M, Mayer LG, Plevy S. The incidence and management of infusion reactions to infliximab: A larger center experience. Am J Gastroenterol 2003;98:1315-24. (Pubitemid 36741529)
12. Kapetanovic M, Larsson L, Truedsson L, Sturfelt G, Saxne T, Geborek P. Predictors of infusion reactions during infliximab treatment in patients with arthritis. Arthritis Res Ther 2006;8:R131.